PMN (ProMIS Neurosciences) Change In Inventory : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Change In Inventory?

ProMIS Neurosciences's change in inventory for the quarter that ended in Dec. 2024 was $0.00 Mil. It means ProMIS Neurosciences's inventory stayed the same from Sep. 2024 to Dec. 2024 .

ProMIS Neurosciences's change in inventory for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means ProMIS Neurosciences's inventory stayed the same from Dec. 2023 to Dec. 2024 .

ProMIS Neurosciences's Total Inventories for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ProMIS Neurosciences Change In Inventory Historical Data

The historical data trend for ProMIS Neurosciences's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Change In Inventory Chart

ProMIS Neurosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

ProMIS Neurosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

ProMIS Neurosciences Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

ProMIS Neurosciences (NAS:PMN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ProMIS Neurosciences's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ProMIS Neurosciences's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ProMIS Neurosciences's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

ProMIS Neurosciences Change In Inventory Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

23J0:Germany 23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Executives

Neil Cashman	director, officer: Chief Scientific Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Madge K. Shafmaster	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel	officer: Chief Medical Officer	C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar	10 percent owner	33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel	director, officer: Chief Executive Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury	officer: Principal Accounting Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant	officer: Chief Operating Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan	officer: Chief Development Officer	PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams	director, officer: Chairman and CEO	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory	director	830 WINTER STREET, WALTHAM MA 02451
Neil K Warma	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman	director	4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2